Leukemia News

Nearly one in six patients with hematologic disorders had a negative COVID-19 vaccination-related antibody response, according to results of a prospective, observational single-center study presented at ASH Annual Meeting and Exposition.

Hispanic individuals appeared considerably underrepresented in a large clinical trial of adolescents and young adults with acute lymphoblastic leukemia, according to study results presented at ASH Annual Meeting and Exposition.

Goals-of-care discussions often occur too late for patients with poor-prognosis, high-risk acute myeloid leukemia, according to study results presented at ASH Annual Meeting and Exposition.

The American Society of Hematology will present this year’s ASH Outstanding Service Award to Peter Marks, MD, PhD.

The FDA approved rituximab in combination with chemotherapy for several pediatric cancer indications.

Tumor gene expression profiles have become standard practice to help guide treatment of several cancer types.

The FDA granted orphan drug designation to CT120, a novel chimeric antigen receptor T-cell therapy, for the treatment of B-cell acute lymphoblastic leukemia.

The FDA granted regenerative medicine advanced therapy designation to CTX110, a chimeric antigen receptor T-cell therapy in development for treatment of relapsed or refractory B-cell malignancies.

In certain settings.

Sepsis is a leading cause of preventable death across the globe, and patients with cancer have a 10 times higher likelihood of developing this life-threatening condition than those without cancer.